Monoclonal antibody specific for the extracellular domain of prostate specific membrane antigen
View Patent ↗The present invention relates to monoclonal antibodies that bind to the extracellular domain of prostate-specific membrane antigen (PSMA), hybridoma cell lines producing the antibodies, and methods of using such antibodies for diagnosis and treatment of cancer. In particular, thirty-five monoclonal antibodies reactive with PSMA expressed on the cell surface are exemplified. Additionally, the present invention relates to a novel protein variant (PSM′) of PSMA detected by a number of the antibodies of the invention. The hydrolase activity of PSMA and PSM′ allows the use of an immunoenzymatic assay for their detection.
1. A method of detecting the presence of PSMA expressed by prostate cancer cells, comprising contacting a sample of cells in vivo with a first monoclonal antibody having an antigen-binding region which binds to a native conformation of PSMA on the surface of live cells and not to denatured PSMA and not to PSMA on the surface of fixed cells and detecting any antibody-bound PSMA on the membrane of the prostate cancer cells.
2. The method of claim 1 , in which the antigen-binding region of the antibody competitively inhibits the immunospecific binding of a second monoclonal antibody to its target epitope, said second antibody being produced by a hybridoma selected from 3C6 having ATCC accession number HB 12491, 4D4 having ATCC accession number HB 12493, and 1G9 having ATCC accession number HB 12495.
3. The method of claim 2 , wherein the second monoclonal antibody is produced by hybridoma 3C6 having ATCC accession number HB 12491.
4. The method of claim 2 , wherein the second monoclonal antibody is produced by hybridoma 4D4 having ATCC accession number HB 12493.
5. The method of claim 2 , wherein the second monoclonal antibody is produced by hybridoma 1G9 having ATCC accession number HB 12495.
6. The method of claim 1 , wherein the antibody is produced by a hybridoma selected from 3C6 having ATCC accession number HB 12491, 4D4 having ATCC accession number HB 12493, and 1G9 having ATCC accession number HB 12495.
7. The method of claim 1 in which the prostate cancer cells are metastatic prostate cancer cells.
8. The method of claim 1 in which the antibody is conjugated to a radioisotope.
9. A method of targeting PSMA expressed by prostate cancer cells in a subject, the method comprising administering to the subject a monoclonal antibody having an antigen-binding region which binds to PSMA expressed on the membrane of live cells and not to denatured PSMA and not to PSMA on the surface of fixed cells whereby the monoclonal antibody targets PSMA on the membrane of the prostate cancer cells in the subject.
10. The method of claim 9 , wherein the antigen-binding region of the antibody competitively inhibits the immunospecific binding of a second monoclonal antibody to its target epitope, said second antibody is produced by a hybridoma selected from 3C6 having ATCC accession number HB 12491, 4D4 having ATCC accession number HB 12493, and 1G9 having ATCC accession number HB 12495.
11. The method of claim 10 , wherein the antibody is produced by a hybridoma selected from 3C6 having ATCC accession number HB 12491, 4D4 having ATCC accession number HB 12493, and 1G9 having ATCC accession number HB 12495.
12. The method of claim 10 , wherein the antibody is conjugated to a radioisotope.
13. A method of targeting PSMA expressed by prostate cancer cells in a subject, the method comprising administering to the subject a first monoclonal antibody having an antigen-binding region which binds to a native conformation of PSMA on the surface of live cells and not to denatured PSMA and not to PSMA on the surface of fixed cells whereby the monoclonal antibody targets PSMA on the membrane of the prostate cancer cells in the subject.
14. The method of claim 13 , wherein the antigen-binding region of the antibody competitively inhibits the immunospecific binding of a second monoclonal antibody to its target epitope, said second antibody is produced by a hybridoma selected from 3C6 having ATCC accession number HB 12491, 4D4 having ATCC accession number HB 12493, and 1G9 having ATCC accession number HB 12495.
15. The method of claim 13 , wherein the antibody is produced by a hybridoma selected from 3C6 having ATCC accession number HB 12491, 4D4 having ATCC accession number HB 12493, and 1G9 having ATCC accession number HB 12495.
16. The method of claim 13 , wherein the antibody is conjugated to a radioisotope.